Popular Trials
Monoclonal Antibodies
Cladribine + Rituximab for Hairy Cell Leukemia
Recruiting3 awardsPhase 2
Houston, Texas
This trial studies how well two drugs, cladribine and rituximab, work together in treating patients with hairy cell leukemia. Cladribine helps stop cancer cells from growing, while rituximab helps the immune system attack cancer cells. The combination aims to be more effective in treating this type of leukemia.
Popular Filters
Trials for HCL Patients
Monoclonal Antibodies
MGD024 for Blood Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial is testing a new drug called MGD024 in patients with certain blood cancers that haven't responded to other treatments. Researchers want to see if MGD024 is safe, how it works in the body, and if it helps fight cancer. Patients will receive the drug periodically, and their response will be monitored regularly.
Immunotoxin
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing the safety of combining two drugs, Rituximab/Ruxience and Moxetumomab pasudotox, to treat hairy cell leukemia or a variant of it. Eligible participants must be 18 or older and the cancer must not have responded to standard therapy.
BRAF Inhibitor
Vemurafenib + Obinutuzumab for Hairy Cell Leukemia
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a combination of two drugs, vemurafenib and obinutuzumab, to treat hairy cell leukemia (HCL) that has not been treated before. The trial will have 28 patients total, and will test the efficacy of the combination treatment. If the treatment is successful, bone marrow aspirate and biopsy will be performed to assess response and evaluate minimal residual disease (MRD).
Trials for MCL Patients
Monoclonal Antibodies
MGD024 for Blood Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial is testing a new drug called MGD024 in patients with certain blood cancers that haven't responded to other treatments. Researchers want to see if MGD024 is safe, how it works in the body, and if it helps fight cancer. Patients will receive the drug periodically, and their response will be monitored regularly.
Chemotherapy
CC-486 + Lenalidomide + Obinutuzumab for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 1
Sacramento, California
This trial is testing a new drug, CC-486, to see if it is effective in treating patients with B-cell lymphoma that has come back or has not responded to treatment. The new drug will be tested in combination with lenalidomide and obinutuzumab.
Anti-tumor antibiotic
Cellular Immunotherapy After Chemotherapy for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back.
Trials With No Placebo
Monoclonal Antibodies
MGD024 for Blood Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial is testing a new drug called MGD024 in patients with certain blood cancers that haven't responded to other treatments. Researchers want to see if MGD024 is safe, how it works in the body, and if it helps fight cancer. Patients will receive the drug periodically, and their response will be monitored regularly.
Immunotoxin
Moxetumomab + Rituximab/Ruxience for Hairy Cell Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing the safety of combining two drugs, Rituximab/Ruxience and Moxetumomab pasudotox, to treat hairy cell leukemia or a variant of it. Eligible participants must be 18 or older and the cancer must not have responded to standard therapy.
BRAF Inhibitor
Vemurafenib + Obinutuzumab for Hairy Cell Leukemia
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a combination of two drugs, vemurafenib and obinutuzumab, to treat hairy cell leukemia (HCL) that has not been treated before. The trial will have 28 patients total, and will test the efficacy of the combination treatment. If the treatment is successful, bone marrow aspirate and biopsy will be performed to assess response and evaluate minimal residual disease (MRD).
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.